New Myeloma Agents Incorporated into NCCN Guidelines
Beginning with bortezomib (Velcade) in 2004, there have been 10 agents approved over the last 12 years for the treatment of patients with multiple myeloma.
Beyond Cost: SITC Addresses Critical Issues to Define the Value of Cancer Immunotherapy
SITC addresses the crucial value of cancer immunotherapy in discussions in a Value of Cancer Immunotherapy Summit.
